Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cimdelirsen

An antisense oligonucleotide targeting the growth hormone receptor (GHR; somatotropin receptor) mRNA, with potential somatotropin-inhibiting activity. Upon subcutaneous administration, cimdelirsen hybridizes with GHR mRNA, which blocks translation of the GHR protein. Reduction of GHR levels in turn decreases the circulating level of insulin-like growth factor-1 (IGF-1). IGF-1 is a hormone that plays an important role in childhood growth and has anabolic effects in adults. Excess production of IGF-1 results in various disease states including acromegaly.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:GHR antisense oligonucleotide IONIS-GHR-LRx
growth hormone receptor antisense oligonucleotide IONIS-GHR-LRx
IONIS-GHR-LRx
LICA drug IONIS-GHR-LRx
ligand-conjugated antisense drug IONIS-GHR-LRx
Code name:IONIS GHR LRX
ISIS-766720
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search